Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Carcinoma, Hepatocellular 147Cholangiocarcinoma 26Liver Neoplasms 17Stomach Neoplasms 13Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 7Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Esophageal Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma 3Advanced Biliary Tract Cancer 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Glandular and Epithelial 2Melanoma 2Hepatitis B 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms Immunotherapy 2Uterine Cervical Neoplasms 1

Interventions

Gemcitabine 4pembrolizumab 3napabucasin 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2Paclitaxel 2Leucovorin 2Fluorouracil 2Cisplatin 2Bevacizumab 2pralsetinib 1linifanib 1durvalumab 1Radiofrequency Ablation 1Pemetrexed 1Nivolumab 1Immunotherapy 1Endoscopic Mucosal Resection 1Cobicistat 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × lenvatinib × Gastrointestinal × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Completed
412 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡